Previous 10 | Next 10 |
2023-05-11 03:30:51 ET Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q1 2023 Earnings Call May 10, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Inovio Pharmaceuticals (INO) Q1 2023 Earnings ...
2023-05-10 19:34:03 ET Inovio Pharmaceuticals, Inc. (INO) Q1 2023 Earnings Conference Call May 10, 2023, 04:30 PM ET Company Participants Thomas Hong - Manager of Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chi...
2023-05-10 16:09:24 ET Inovio Pharmaceuticals press release ( NASDAQ: INO ): Q1 GAAP EPS of -$0.16 misses by $0.02 . Revenue of $0.11M (-45.0% Y/Y) misses by $0.17M . Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory ...
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights PR Newswire Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw ...
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023 PR Newswire Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) ...
Achieved positive operating cash flow with adjusted EBITDA of $4.1 million FWA and cloud solutions business comprised 53% of revenue, up 35% year-over-year Gross margin improved to 36% on the strength of FWA and cloud business Inseego Corp. (Nasdaq: INSG) (the ȁ...
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023 PR Newswire PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protec...
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023 PR Newswire Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5 ...
2023-04-26 09:21:49 ET The European Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Inovio ( NASDAQ: INO ) application seeking orphan drug designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP). RRP is a rare chr...
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107 PR Newswire European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa. , ...
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
2024-07-16 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today announced that the company will release its financial results for the second quarter of 2024, ended June 30, 2024, after the financial ...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respi...